Sensus Q3 2026 call offers first real test of CPT-driven turnaround, but caution remains

What happened

Sensus Healthcare held its Q3 2026 earnings call on November 13, 2026, reporting results for the quarter ended September 30, 2026, which is the third full quarter under the new SRT-specific CMS CPT codes that took effect January 1, 2026. The call likely provided management's commentary on whether those codes have driven increased system orders, Fair Deal treatment volumes, and diversification away from the single large U.S. customer that previously accounted for over 70% of revenue. While the transcript title alone offers no financial details, the DeepValue master report as of early 2026 had rated the stock WAIT with an attractive entry near $4.00, citing execution and concentration risk and the need for 1-2 confirming quarters of CPT-driven traction. Given that the stock traded around $4.99 in late January 2026, the Q3 2026 call may reveal whether the anticipated inflection materialized or whether growth remains stalled, gross margins stay depressed, and customer concentration persists. Without specific figures, one must remain skeptical of management's narrative, as earlier calls have sometimes painted optimistic pictures that later disappointed, so the key metrics to watch are revenue growth, Fair Deal volumes, gross margin, and revenue concentration.

Implication

The Q3 2026 earnings call is a critical checkpoint for the thesis that new CPT codes accelerate SRT adoption and reduce customer concentration. If the call discloses stronger than expected system orders, growth in Fair Deal treatment volumes, and gross margins trending above 45-50%, the bullish case may gain traction, supporting a move toward the $6-$8.50 scenario. Conversely, if revenue remains below 2024 peak, gross margin remains sub-45%, or the largest customer still dominates, the bear case near $3 becomes more plausible and the stock could re-rate lower. The DeepValue report's WAIT rating implies that the risk-reward is not compelling at current prices without confirmation, so investors should require robust data demonstrating durable demand and margin improvement. Additionally, watch for management's tone and any forward guidance, as overly optimistic statements without order backlog or utilization data should be discounted, and legal overhang remains a wildcard.

Thesis delta

No material shift yet from the WAIT stance; the Q3 2026 call is the first opportunity to validate the CPT-driven inflection, but without specific disclosures, the thesis remains unchanged. The DeepValue report's cautious view stands until tangible evidence of diversified growth and margin expansion appears.